[go: up one dir, main page]

AR056475A1 - Formulacion solida estable de sertinodl - Google Patents

Formulacion solida estable de sertinodl

Info

Publication number
AR056475A1
AR056475A1 ARP060103764A ARP060103764A AR056475A1 AR 056475 A1 AR056475 A1 AR 056475A1 AR P060103764 A ARP060103764 A AR P060103764A AR P060103764 A ARP060103764 A AR P060103764A AR 056475 A1 AR056475 A1 AR 056475A1
Authority
AR
Argentina
Prior art keywords
sertinodl
solid formulation
stable solid
sertindole
pharmaceutical composition
Prior art date
Application number
ARP060103764A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR056475A1 publication Critical patent/AR056475A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composicion farmacéutica que comprende sertindol y un agente protector que absorbe radicacion con una longitud de onda por debajo de 400 nm. La presente se refiere también al uso de sertindol para la preparacion de una composicion farmacéutica que comprende sertindol y una capa de recubrimiento que comprende dicho agente protector, tal como oxido de hierro, para el tratamiento de esquizofrenia.
ARP060103764A 2005-09-08 2006-08-29 Formulacion solida estable de sertinodl AR056475A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200501255 2005-09-08

Publications (1)

Publication Number Publication Date
AR056475A1 true AR056475A1 (es) 2007-10-10

Family

ID=37697999

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103764A AR056475A1 (es) 2005-09-08 2006-08-29 Formulacion solida estable de sertinodl

Country Status (17)

Country Link
EP (1) EP1924261A1 (es)
JP (1) JP2009507051A (es)
KR (1) KR20080042102A (es)
CN (1) CN101257906A (es)
AR (1) AR056475A1 (es)
AU (1) AU2006322460A1 (es)
BR (1) BRPI0615630A2 (es)
CA (1) CA2621866A1 (es)
EA (1) EA013167B1 (es)
IL (1) IL189541A0 (es)
MX (1) MX2008002290A (es)
NO (1) NO20081721L (es)
NZ (1) NZ565330A (es)
TW (1) TW200738239A (es)
UA (1) UA97349C2 (es)
WO (1) WO2007065448A1 (es)
ZA (1) ZA200801169B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
CN106344533A (zh) * 2009-01-29 2017-01-25 大日本住友制药株式会社 具有内核的口腔崩解片剂
FR2943061B1 (fr) * 2009-03-13 2011-02-25 Rhodia Operations Composes organophosphores, systemes catalytiques comprenant ces composes et procede d'hydrocyanation ou d'hydroformylation utilisant ces systemes catalytiques
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
JP6491093B2 (ja) 2012-07-16 2019-03-27 フィブロジェン インコーポレイテッド プロリルヒドロキシラーゼ阻害剤の結晶形態
DK3003284T3 (da) 2013-06-06 2020-03-30 Fibrogen Inc Farmaceutiske formuleringer af en hif-hydroxylase-inhibitor
CN105636585B (zh) 2013-11-19 2020-02-07 西佳技术公司 微粉化特考韦瑞一水化物的再水化
JP2018172361A (ja) * 2016-10-14 2018-11-08 大原薬品工業株式会社 光安定性を改善した、デュロキセチンを含有する固形製剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04346929A (ja) * 1991-05-22 1992-12-02 Takada Seiyaku Kk 光に安定なメシル酸ブロモクリプチン製剤
JP2000507544A (ja) * 1996-03-25 2000-06-20 イーライ・リリー・アンド・カンパニー 痛みの治療方法
ZA973433B (en) * 1996-04-24 1997-12-10 Shionogi & Co A sertindole-containing preparation and a method for producing the same.
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses

Also Published As

Publication number Publication date
KR20080042102A (ko) 2008-05-14
MX2008002290A (es) 2008-03-14
BRPI0615630A2 (pt) 2016-11-16
WO2007065448A1 (en) 2007-06-14
IL189541A0 (en) 2008-08-07
CA2621866A1 (en) 2007-06-14
EA200800774A1 (ru) 2008-06-30
EA013167B1 (ru) 2010-02-26
NO20081721L (no) 2008-04-08
EP1924261A1 (en) 2008-05-28
AU2006322460A1 (en) 2007-06-14
TW200738239A (en) 2007-10-16
JP2009507051A (ja) 2009-02-19
NZ565330A (en) 2011-06-30
CN101257906A (zh) 2008-09-03
ZA200801169B (en) 2010-07-28
UA97349C2 (uk) 2012-02-10

Similar Documents

Publication Publication Date Title
MX2008011085A (es) Composiciones antimicrobianas y metodos para sellar cateteres.
CL2012002844A1 (es) Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende; y su uso en el tratamiento de un trastorno proliferativo de celulas tal como cancer (divisional solicitud nº 311-07).
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
UY31209A1 (es) Uso de homo y copolimeros para la estabilización de formulaciones de principios activos
BR112015007083A2 (pt) inibidores de histona demetilases
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
AR065143A1 (es) Composicion del antitranspirante/desodorante
ECSP10010559A (es) Compuestos heterociclicos novedosos y usos de los mismos
CL2008003473A1 (es) Compuestos derivados de fenilpiperidina sustituidos por heterociclos; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso en el tratamiento del trastorno cardiovasculares, tromboembolicos y tumorales; usos in vitro.
CL2007002234A1 (es) Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
CL2011003350A1 (es) Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CL2007002994A1 (es) Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
CL2008001024A1 (es) Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades cardiovasculares, parkinson, enfermedades inflamatorias, esclerosis multiple, cancer, entre otras
UY29410A1 (es) Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones.
MX345130B (es) Eficiencia aumentada de composiciones de protección solar.
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
UY33984A (es) Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
CL2008001533A1 (es) Formulacion que comprende triazinonas y compuestos o complejos ferricos, utiles para preparar medicamentos para uso veterinario contra la coccidiosis y deficiencias de hierro.
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
CL2007003587A1 (es) Compuestos derivados de pirimidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para tratar o prevenir la infeccion de la hepatitis c.
NO20081721L (no) Stabil fast formulering av sertindol

Legal Events

Date Code Title Description
FA Abandonment or withdrawal